ストックスクリーナーアプリを入手
3.47
1.14%
-0.04
アフターアワーズ：
3.47
前日終値:
$3.51
開ける：
$3.44
24時間の取引高:
460.31K
Relative Volume:
0.80
時価総額：
$163.11M
収益：
-
当期純損益:
$-32.74M
株価収益率:
-4.2317
EPS:
-0.82
ネットキャッシュフロー:
$-24.89M
1週間 パフォーマンス:
-4.14%
1か月 パフォーマンス:
+0.58%
6か月 パフォーマンス:
-74.39%
1年 パフォーマンス:
-63.24%
1日の値動き範囲:
$3.34
$3.515
1週間の範囲:
$3.34
$3.68
52週間の値動き範囲:
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
名前
Third Harmonic Bio Inc
セクター
電話
(209) 727-2457
住所
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
3.47 | 163.11M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-07 | 開始されました | Raymond James | Outperform |
| 2022-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 開始されました | Cowen | Outperform |
| 2022-10-10 | 開始されました | Jefferies | Buy |
| 2022-10-10 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Third Harmonic Bio Inc (THRD) 最新ニュース
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Hold Rating for Third Harmonic Bio, Inc. Amid Strategic Exploration and Cautious Development Approach - TipRanks
Stifel Downgrades Third Harmonic Bio (THRD) - MSN
Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23 - MarketScreener
Third Harmonic Bio Reports 2024 Financial Results and Strategic Plans - TipRanks
Third Harmonic Bio reports FY24 EPS ($1.09) vs. (78c) last year - TipRanks
Stifel cuts Third Harmonic stock rating to hold, slashes target to $5 - Investing.com
Third Harmonic Bio Q4 Net Income USD -13.1 Million - Marketscreener.com
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Third Harmonic Bio, Inc. Announces Rise In Full Year Profit - Nasdaq
Third Harmonic's $285M War Chest Powers Phase 2 CSU Drug Development Amid Strategic Shift - Stock Titan
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech
Third Harmonic Bio Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
2025 R&D layoffs tracker: 53,686 and counting - R&D World
Third Harmonic Bio Advances THB335 for Inflammatory Diseases - TipRanks
THB-335 counteracts cutaneous anaphylaxis in vivo - BioWorld Online
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study - Yahoo Finance
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Third Harmonic Bio Inc (THRD) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):